n-Butyl lactate structure
|
Common Name | n-Butyl lactate | ||
|---|---|---|---|---|
| CAS Number | 138-22-7 | Molecular Weight | 146.184 | |
| Density | 1.0±0.1 g/cm3 | Boiling Point | 189.4±8.0 °C at 760 mmHg | |
| Molecular Formula | C7H14O3 | Melting Point | −28 °C(lit.) | |
| MSDS | Chinese USA | Flash Point | 69.4±0.0 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
| Name | Butyl lactate |
|---|---|
| Synonym | More Synonyms |
| Density | 1.0±0.1 g/cm3 |
|---|---|
| Boiling Point | 189.4±8.0 °C at 760 mmHg |
| Melting Point | −28 °C(lit.) |
| Molecular Formula | C7H14O3 |
| Molecular Weight | 146.184 |
| Flash Point | 69.4±0.0 °C |
| Exact Mass | 146.094299 |
| PSA | 46.53000 |
| LogP | 0.88 |
| Vapour density | 5.04 (vs air) |
| Vapour Pressure | 0.2±0.8 mmHg at 25°C |
| Index of Refraction | 1.432 |
| Water Solubility | 42 g/L (25 ºC) |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | Eyeshields;full-face respirator (US);Gloves;multi-purpose combination respirator cartridge (US);type ABEK (EN14387) respirator filter |
| Hazard Codes | Xi:Irritant; |
| Risk Phrases | R36/37/38 |
| Safety Phrases | S26-S36-S37/39 |
| WGK Germany | 2 |
| RTECS | OD4025000 |
| Packaging Group | I; II; III |
| HS Code | 2918110000 |
| Precursor 10 | |
|---|---|
| DownStream 10 | |
| HS Code | 2918110000 |
|---|---|
| Summary | 2918110000. lactic acid, its salts and esters. VAT:17.0%. Tax rebate rate:13.0%. Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward). MFN tariff:6.5%. General tariff:30.0% |
|
An insight on human skin penetration of diflunisal: lipogel versus hydrogel microemulsion.
Drug Dev. Ind. Pharm. 41(1) , 141-7, (2014) Diflunisal is a NSAID used in acute and long term management of pain and inflammation associated with osteoarthritis, rheumatoid arthritis and symptoms of primary dysmenorrhea. However, its oral use i... |
|
|
Optimization, ex vivo permeation, and stability study of lipid nanocarrier loaded gelatin capsules for treatment of intermittent claudication.
Int. J. Nanomedicine 10 , 4459-78, (2015) In this study, an optimized nanodispersible oral dosage form (containing a lactate ester) was developed for cilostazol (CZL). CZL is a phosphodiesterase inhibitor used for intermittent claudication. W... |
|
|
Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique.
Int. J. Pharm. 257(1-2) , 153-60, (2003) A preparation method for nanoparticles based on the emulsification of a butyl lactate or benzyl alcohol solution of a solid lipid in an aqueous solution of different emulsifiers, followed by dilution ... |
| Propanoic acid, 2-hydroxy-, butyl ester |
| UNII:0UI63W814U |
| MFCD00004519 |
| n-Butyl lactate |
| Lactic Acid Butyl Ester |
| Butyl 2-hydroxypropanoate |
| EINECS 205-316-4 |
| Butyl 2-Hydroxypropionate |
| Butyl Lactate |